Lilly is racing to cement its leadership by developing new injectables and expanding into oralsthe pharmas next generation oral GLP-1 agonist orforglipron recently showed injectable-like effects in a Phase III trialbut faces a potential threat from investigational therapies that are dosed less frequently

Signs you're ready to move to the next dose: GI symptoms (nausea, vomiting, diarrhea) have resolved or are minimal for at least 7 consecutive days Appetite suppression remains noticeable but you sense a plateau effect developing at the current dose You have completed at least 4 full weeks at the current dose level You have no significant intercurrent illness that might confuse attribution of new symptoms Signs to wait: Ongoing nausea or vomiting, even if mild, at the end of the current dose phase A recent GI illness (unrelated to the medication) that makes it hard to attribute current symptoms A major life stressor or schedule disruption that might amplify side effects Fewer than 4 weeks at the current dose, regardless of how you feel When in doubt, an additional week at the current dose costs very little
What quality standard does this article attribute to compounded preparations
Learn more about Benzoic Acid Disodium EDTA is a chelating agent
Your clinician should perform a comprehensive evaluation at your first visit, including a discussion of benefits and possible side effects, and provide a schedule for gradually increasing your GLP-1 dose
Too concentrated, and each injection delivers more than intended